Targeted, Disease-modifying ProgramA focused pipeline program (STA363) aimed at underlying disc pathology gives the company a clear product strategy and potential clinical differentiation versus symptomatic therapies. This structural therapeutic focus can create durable market positioning if clinical proof points are achieved.

Improving Loss And Cash Burn TrendsNarrowing EBIT losses and reduced operating cash burn indicate improving operational efficiency and extend runway without immediate financing. Sustained improvement increases probability of reaching clinical milestones and reduces near-term dilution risk versus a static burn profile.

Very Low Financial LeverageA zero debt position lowers fixed financial obligations and interest exposure for a pre-revenue biotech. This structural balance-sheet strength improves strategic flexibility for R&D financing, partnerships, or milestone-based funding without debt servicing pressure.

Bears Say

Pre-revenue Commercial RiskAbsence of revenue means the firm remains wholly dependent on external capital and development success. Long-term commercial viability hinges on clinical outcomes and successful market entry, making durable cash generation and self-funding unlikely in the near term.

Persistent Negative Operating Cash FlowOngoing negative operating cash flows require recurrent financing to sustain operations. While burn is improving, continued negative free cash flow preserves structural liquidity risk and may force dilutive financings or partnerships before revenues materialize.

Eroding Equity And Asset BaseA materially shrinking equity and asset base reflects value erosion from sustained losses and weak capitalization. This reduces financial resilience, increases vulnerability to adverse funding conditions, and can impair long-term strategic options including partnering or commercialization.

4K4 FAQ

What was Stayble Therapeutics AB’s price range in the past 12 months?

Stayble Therapeutics AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.

What is Stayble Therapeutics AB’s market cap?

Stayble Therapeutics AB’s market cap is €1.03M.

When is Stayble Therapeutics AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Stayble Therapeutics AB’s earnings last quarter?

Currently, no data Available

Is Stayble Therapeutics AB overvalued?

According to Wall Street analysts Stayble Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Stayble Therapeutics AB pay dividends?

Stayble Therapeutics AB does not currently pay dividends.

What is Stayble Therapeutics AB’s EPS estimate?

Stayble Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Stayble Therapeutics AB have?

Stayble Therapeutics AB has 64,359,795 shares outstanding.

What happened to Stayble Therapeutics AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Stayble Therapeutics AB?

Currently, no hedge funds are holding shares in DE:4K4

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Stayble Therapeutics AB

Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.